DIAN-TU selected LECANEMAB as the basic anti-amyloid protein in the clinical trial of treating dominant Alzheimer's disease with TAU as the target to evaluate the effect of exploratory treatment

As more and more clinical research evidence shows that targeting amyloid can reduce Alzheimer's disease (AD) biomarkers, the head of Tau NexGen clinical trials chose Eisai’s exploratory anti-amyloid β ( Aβ) fibrillary antibody lecanemab as a basic anti-amyloid drug

The purpose of the Tau NexGen study is to evaluate the safety, tolerability, biomarkers and cognitive efficacy of exploratory therapy in patients with Alzheimer's disease-causing gene mutations

It is known that people with a dominant genetic Alzheimer's disease (DIAD) mutation will develop AD and may develop symptoms at the same age as the affected parents, usually in their 50s, 40s or even 30s Years old

In the revised Tau NexGen study, symptomatic subjects will receive lecanemab for six months and then be randomly assigned to receive an anti-tau drug or a placebo

By staggering the drugs, researchers will be able to evaluate the effects of anti-tau drugs individually before evaluating the effects of the two drugs together

"As more and more evidence shows that removing amyloid plaques has a biologically beneficial effect on amyloid and tau protein, we believe that it will also target the pathology of Alzheimer's disease-amyloid plaques and amyloid plaques.

Eisai's anti-MTBR tau antibody E2814 was selected as the first exploratory therapy among the anti-tau drugs of Tau NexGen, the pioneering dominant genetic Alzheimer's network trial unit, which was originally designed to target the tau protein

"Eisai is proud that our exploratory anti-amyloid beta fibril antibody lecanemab has been selected as the basic anti-amyloid drug in this research field

Eisai positions neurology as a key therapeutic area, and will continue to innovate in the development of new drugs based on cutting-edge neurological research, and seek further help to improve diseases with high unmet needs (such as dementia including AD).